Welcome to CEVEC Pharmaceuticals

CEVEC is a global solution provider focussing on the development of top notch human expression systems with highest ethical standards. Our platform expression technologies CAP and CAP-T are based on specific, amniocyte derived human cell lines.
CAP and CAP-T are designed for stable and transient protein production and achieve highest protein yields with authentic human glycosylation patterns.
We have a high focus on research and development, production and marketing of our cell systems for protein and vaccine production accompanied by our development of selected “bio-better” and “bio-superior” candidates.
> Read More

2011, July

CEVEC Raises €6M to Grow CAP® Technol. Based Protein & Vaccine Business

Cologne, Germany, July 25, 2011 / B3C newswire / - CEVEC Pharmaceuticals, licensing its human CAP® Technology based expression system for proteins and vaccines, today announced the closing of a €6M financing round. NRW.BANK and Creathor Venture Fonds led this round which included the participation from current investors, a group of private and institutional investors and ERP Startfonds of KfW bank.

> READ MORE

Stable Expression

CAP

Stable expression describes the production of recombinant proteins due to integration of the respective gene expression cassette into the chromosome of the producer cell line. In most cases, the gene of interest is integrated into the chromosome via non-homologous recombination in varying copy numbers.

> READ MORE

Transient Expression

CAP-T

Transient expression stands for the temporary expression of a protein. For many applications, e.g., drug discovery, high-throughput screening, assay development or early stage pre-clinical drug development, transient expression offers the advantages of achieving both fast process times and high yields. It is usually achieved by simply transfecting the gene of interest as circular plasmid into the respective producer cells.

> READ MORE